The Vanguard Group Discloses Position in Avadel Pharmaceuticals

The Vanguard Group, Inc. has released Form 8.3 as per the requirements of the Irish Takeover Panel Act. This disclosure is concerning Avadel Pharmaceuticals plc, relating to relevant securities they hold a substantial interest in. As of December 8, 2025, Vanguard reported owning 5,583,006 ordinary shares, representing a 5.73% stake in Avadel.

Recent transactions included the purchase of 3,731 shares and the sale of 1,434 shares, both at a unit price of $21.32. No derivative transactions were reported in this disclosure. Furthermore, there are no relevant indemnity or option agreements or any arrangements with other parties concerning derivatives.

This transparency is part of the compliance with takeover regulations, ensuring full disclosure of significant holdings in Avadel Pharmaceuticals by investment firms.